Loading...
•
Sep 30, 2021
Mesa Labs Q2 2022 Earnings Report
Mesa Labs reported an increase in revenues and net income but a decrease in operating income for Q2 2022.
Key Takeaways
Mesa Laboratories reported a 12% increase in revenues to $35.84 million for the second quarter of fiscal year 2022. Operating income decreased by 6% to $4.201 million, while net income increased by 39% to $3.720 million, or $0.70 per diluted share.
Revenues increased by 12% compared to the same quarter last year.
Operating income decreased by 6% compared to the same quarter last year.
Net income increased by 39% compared to the same quarter last year.
Sterilization and Disinfection Control division saw 21% organic growth.
Mesa Labs
Mesa Labs
Mesa Labs Revenue by Segment
Revenue by Segment
Sterilization & Disinfection Control Revenue
CapyFin.comBiopharmaceutical Development Revenue
CapyFin.com Forward Guidance
Mesa Labs anticipates continued volatility from the COVID pandemic, regulatory and tax environment changes, and strong competition for talent.
Positive Outlook
- The Mesa Way and strong underlying markets have resulted in robust year to date organic growth of 14% versus 1H21.
- Combination with Agena Bioscience creates new opportunities within Clinical Genomics tools.
- Reinforces core strategy of being a leader in life sciences and quality control tools.
- Adds a genomic complement to protein analytics capabilities.
- Adds talent to help drive Mesa’s long-term growth.
Challenges Ahead
- Continued volatility from the COVID pandemic on both demand and supply.
- Changing regulatory and tax environments.
- Strong competition for attractive talent across our businesses.
- Longer term disruptions to both component supply.
- Disruptions to the labor markets.
Revenue & Expenses
Visualization of income flow from segment revenue to net income